Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Lorente

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Clinical Genitourinary Cancer|June 3, 2017
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden HospitalDiletta Bianchini, David Lorente, Pasquale Rescigno, et al.
European Urology|March 8, 2020
Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate CancerDavid Lorente, Elena Castro, Rebeca Lozano, et al.
European Urology Oncology|May 18, 2019
Consensus Statement on Circulating Biomarkers for Advanced Prostate CancerSemini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, et al.
Cancers|June 2, 2021
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) PatientsRebeca Lozano, David Lorente, Isabel M Aragon, et al.
Urologic Oncology|February 1, 2025
Multicenter study of active surveillance for small renal masses: Real world practice patternTarek Ajami, Eric Villalba Lázaro, Enrique Trilla Herrera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2015
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationJean Sebastien Frenel, Suzanne Carreira, Jane Goodall, et al.
British Journal of Cancer|August 23, 2018
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)Nuria Romero-Laorden, Rebeca Lozano, Anuradha Jayaram, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 5, 2026
Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish 'Cambados annual meeting'Sergio Vázquez-Estévez, Martín Lázaro-Quintela, Daniel Pérez-Fentes, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2021
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancerRebeca Lozano, Daniela C Salles, Shahneen Sandhu, et al.
Melanoma Research|March 29, 2023
Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational studyJosé L Manzano, Juan Martin-Liberal, Luis A Fernández-Morales, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Clinical Genitourinary Cancer|June 3, 2017
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden HospitalDiletta Bianchini, David Lorente, Pasquale Rescigno, et al.
European Urology|March 8, 2020
Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate CancerDavid Lorente, Elena Castro, Rebeca Lozano, et al.
European Urology Oncology|May 18, 2019
Consensus Statement on Circulating Biomarkers for Advanced Prostate CancerSemini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, et al.
Cancers|June 2, 2021
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) PatientsRebeca Lozano, David Lorente, Isabel M Aragon, et al.
Urologic Oncology|February 1, 2025
Multicenter study of active surveillance for small renal masses: Real world practice patternTarek Ajami, Eric Villalba Lázaro, Enrique Trilla Herrera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2015
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationJean Sebastien Frenel, Suzanne Carreira, Jane Goodall, et al.
British Journal of Cancer|August 23, 2018
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)Nuria Romero-Laorden, Rebeca Lozano, Anuradha Jayaram, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 5, 2026
Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish 'Cambados annual meeting'Sergio Vázquez-Estévez, Martín Lázaro-Quintela, Daniel Pérez-Fentes, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2021
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancerRebeca Lozano, Daniela C Salles, Shahneen Sandhu, et al.
Melanoma Research|March 29, 2023
Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational studyJosé L Manzano, Juan Martin-Liberal, Luis A Fernández-Morales, et al.
Pageof 8